92 Views | 47 Downloads
pls47@case.edu or dmitryshay@emory.edu
We are thankful to Eric Irons (Buffalo University) for analyzing in vitro properties of Ad5-Lam1 virus and Neetu M. Gulati for assistance with preparing Ad5-3M cryo-EM grids.
D.M.S. has equity interest and is a chief scientific officer of AdCure Bio, which develops adenovirus technologies for therapeutic use. D.M.S. is an inventor on issued US patents No. 9,982,276, Penton-mutated, integrin-retargeted adenovirus vectors with reduced toxicity and their use; and No.10,376,549, Detargeted adenovirus variants and related methods; and pending US patent application 16/460,160 and European patent application 16740545.5, Detargeted adenovirus variants and related methods, submitted by AdCure Bio. All other authors declare that they have no competing interests.
The authors acknowledge the use of instruments at the Electron Imaging Center for NanoMachines supported by NIH (1S10RR23057, 1S10OD018111, and 1U24GM116792), NSF (DBI-1338135) and CNSI at UCLA. We thank the Case Western Reserve University High Performance Computing staff for their assistance with campus computing resources. Preliminary image processing was performed using the Extreme Science and Engineering Discovery Environment (XSEDE), which is supported by National Science Foundation grant number ACI-1548562. This work used the XSEDE Large Memory Nodes (Bridges Large) at the Pittsburgh Supercomputing Center through allocation MCB170163.
This work was supported by NIH grant AI107960 to D.M.S and P.L.S. and by NIH grant AI065429, David C. Lowance Endowment Fund, and Children’s Healthcare of Atlanta Research Trust to D.M.S. C.C.E. acknowledges support from the NIH T32 GM008803 training grant. The analysis of Ad5/35-3M was supported by funding from AdCure Bio to D.M.S.